MAZE

Maze Therapeutics Stock Analysis

AI Rating

Good
  • Quality3/10
  • Growth↑ 6/10
  • Momentum↑ 9/10
Maze Therapeutics sales and earnings growth
MAZE Growth
Good
  • Revenue Y/Y↓ -100.00%
  • EPS Y/Y↑ 84.35%
  • FCF Y/Y↓ -239.95%
Maze Therapeutics gross and profit margin trends
MAZE Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -208.60%
Maze Therapeutics net debt vs free cash flow
MAZE Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Maze Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗